Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore

Vivianne Shih, Alexandre Chan, Feng Xie, Yu Ko

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: In Singapore, breast cancer is the leading female malignancy and its incidence has increased threefold over the past decades. For treatment of postmenopausal, hormone receptor positive early stage breast cancer, tamoxifen or aromatase inhibitors such as anastrozole are prescribed either as first-line therapy or sequentially. Currently, anastrozole is patented with a higher drug cost compared with tamoxifen. Hence, the aim of this study was to conduct an economic evaluation of anastrozole versus tamoxifen in early stage breast cancer. Methods:A Markov model with a lifetime horizon was developed by using results from the Arimidex, Tamoxifen, Alone or in Combination trial. Direct medical costs were estimated by billing data obtained via financial electronic databases. Utility scores were elicited from 20 experienced oncology nurses using the visual analogue scale. Cost per quality-adjusted life-years was calculated by using the societal perspective. A discount rate of 3% for both charges (expressed in 2010 Singapore dollars) and benefits was used. Results: At an additional cost of S $17,597, anastrozole treatment resulted in a gain of 0.085 life-year survival and 0.154 quality-adjusted life-year. The incremental cost-effectiveness ratio of anastrozole was S $207,402 per life-year gained and S $114,061 per quality-adjusted life-year gained compared with tamoxifen. Conclusion:This is the first economic evaluation that used 10-year results from the Arimidex, Tamoxifen, Alone or in Combination trial and utility elicited from the local population. If the World Health Organization's recommendation of 1 to 3 gross domestic product range is an acceptable threshold, anastrozole is deemed cost-effective compared with tamoxifen in the treatment of early stage breast cancer.

Original languageEnglish
Pages (from-to)46-53
Number of pages8
JournalValue in Health Regional Issues
Volume1
Issue number1
DOIs
Publication statusPublished - 2012
Externally publishedYes

Fingerprint

Singapore
Tamoxifen
Cost-Benefit Analysis
Breast Neoplasms
Quality-Adjusted Life Years
Costs and Cost Analysis
Gross Domestic Product
Aromatase Inhibitors
Drug Costs
anastrozole
Breast cancer
Economic evaluation
Therapeutics
Visual Analog Scale
Costs
Quality-adjusted life years
Nurses
Databases
Hormones
Incidence

Keywords

  • Anastrozole breast cancer
  • Cost-effectiveness analysis
  • CostutilityAnalysis
  • Tamoxifen

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Economics, Econometrics and Finance (miscellaneous)

Cite this

Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. / Shih, Vivianne; Chan, Alexandre; Xie, Feng; Ko, Yu.

In: Value in Health Regional Issues, Vol. 1, No. 1, 2012, p. 46-53.

Research output: Contribution to journalArticle

@article{cad3a0d398bb433a8a4edc9302dc98e2,
title = "Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore",
abstract = "Objectives: In Singapore, breast cancer is the leading female malignancy and its incidence has increased threefold over the past decades. For treatment of postmenopausal, hormone receptor positive early stage breast cancer, tamoxifen or aromatase inhibitors such as anastrozole are prescribed either as first-line therapy or sequentially. Currently, anastrozole is patented with a higher drug cost compared with tamoxifen. Hence, the aim of this study was to conduct an economic evaluation of anastrozole versus tamoxifen in early stage breast cancer. Methods:A Markov model with a lifetime horizon was developed by using results from the Arimidex, Tamoxifen, Alone or in Combination trial. Direct medical costs were estimated by billing data obtained via financial electronic databases. Utility scores were elicited from 20 experienced oncology nurses using the visual analogue scale. Cost per quality-adjusted life-years was calculated by using the societal perspective. A discount rate of 3{\%} for both charges (expressed in 2010 Singapore dollars) and benefits was used. Results: At an additional cost of S $17,597, anastrozole treatment resulted in a gain of 0.085 life-year survival and 0.154 quality-adjusted life-year. The incremental cost-effectiveness ratio of anastrozole was S $207,402 per life-year gained and S $114,061 per quality-adjusted life-year gained compared with tamoxifen. Conclusion:This is the first economic evaluation that used 10-year results from the Arimidex, Tamoxifen, Alone or in Combination trial and utility elicited from the local population. If the World Health Organization's recommendation of 1 to 3 gross domestic product range is an acceptable threshold, anastrozole is deemed cost-effective compared with tamoxifen in the treatment of early stage breast cancer.",
keywords = "Anastrozole breast cancer, Cost-effectiveness analysis, CostutilityAnalysis, Tamoxifen",
author = "Vivianne Shih and Alexandre Chan and Feng Xie and Yu Ko",
year = "2012",
doi = "10.1016/j.vhri.2012.03.013",
language = "English",
volume = "1",
pages = "46--53",
journal = "Value in Health Regional Issues",
issn = "2212-1099",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore

AU - Shih, Vivianne

AU - Chan, Alexandre

AU - Xie, Feng

AU - Ko, Yu

PY - 2012

Y1 - 2012

N2 - Objectives: In Singapore, breast cancer is the leading female malignancy and its incidence has increased threefold over the past decades. For treatment of postmenopausal, hormone receptor positive early stage breast cancer, tamoxifen or aromatase inhibitors such as anastrozole are prescribed either as first-line therapy or sequentially. Currently, anastrozole is patented with a higher drug cost compared with tamoxifen. Hence, the aim of this study was to conduct an economic evaluation of anastrozole versus tamoxifen in early stage breast cancer. Methods:A Markov model with a lifetime horizon was developed by using results from the Arimidex, Tamoxifen, Alone or in Combination trial. Direct medical costs were estimated by billing data obtained via financial electronic databases. Utility scores were elicited from 20 experienced oncology nurses using the visual analogue scale. Cost per quality-adjusted life-years was calculated by using the societal perspective. A discount rate of 3% for both charges (expressed in 2010 Singapore dollars) and benefits was used. Results: At an additional cost of S $17,597, anastrozole treatment resulted in a gain of 0.085 life-year survival and 0.154 quality-adjusted life-year. The incremental cost-effectiveness ratio of anastrozole was S $207,402 per life-year gained and S $114,061 per quality-adjusted life-year gained compared with tamoxifen. Conclusion:This is the first economic evaluation that used 10-year results from the Arimidex, Tamoxifen, Alone or in Combination trial and utility elicited from the local population. If the World Health Organization's recommendation of 1 to 3 gross domestic product range is an acceptable threshold, anastrozole is deemed cost-effective compared with tamoxifen in the treatment of early stage breast cancer.

AB - Objectives: In Singapore, breast cancer is the leading female malignancy and its incidence has increased threefold over the past decades. For treatment of postmenopausal, hormone receptor positive early stage breast cancer, tamoxifen or aromatase inhibitors such as anastrozole are prescribed either as first-line therapy or sequentially. Currently, anastrozole is patented with a higher drug cost compared with tamoxifen. Hence, the aim of this study was to conduct an economic evaluation of anastrozole versus tamoxifen in early stage breast cancer. Methods:A Markov model with a lifetime horizon was developed by using results from the Arimidex, Tamoxifen, Alone or in Combination trial. Direct medical costs were estimated by billing data obtained via financial electronic databases. Utility scores were elicited from 20 experienced oncology nurses using the visual analogue scale. Cost per quality-adjusted life-years was calculated by using the societal perspective. A discount rate of 3% for both charges (expressed in 2010 Singapore dollars) and benefits was used. Results: At an additional cost of S $17,597, anastrozole treatment resulted in a gain of 0.085 life-year survival and 0.154 quality-adjusted life-year. The incremental cost-effectiveness ratio of anastrozole was S $207,402 per life-year gained and S $114,061 per quality-adjusted life-year gained compared with tamoxifen. Conclusion:This is the first economic evaluation that used 10-year results from the Arimidex, Tamoxifen, Alone or in Combination trial and utility elicited from the local population. If the World Health Organization's recommendation of 1 to 3 gross domestic product range is an acceptable threshold, anastrozole is deemed cost-effective compared with tamoxifen in the treatment of early stage breast cancer.

KW - Anastrozole breast cancer

KW - Cost-effectiveness analysis

KW - CostutilityAnalysis

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84984586041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984586041&partnerID=8YFLogxK

U2 - 10.1016/j.vhri.2012.03.013

DO - 10.1016/j.vhri.2012.03.013

M3 - Article

AN - SCOPUS:84984586041

VL - 1

SP - 46

EP - 53

JO - Value in Health Regional Issues

JF - Value in Health Regional Issues

SN - 2212-1099

IS - 1

ER -